BridgeBio Pharma, Inc. (BBIO)
Health Care · Rare genetic disease biopharmaceuticals · Nasdaq
BridgeBio translates genetic science into medicines for rare genetic diseases through a decentralized portfolio model, with an FDA-approved lead product in transthyretin amyloidosis and multiple late-stage programs approaching commercialization.
What BridgeBio Pharma, Inc. does
BridgeBio Pharma is a commercial-stage, multi-product biopharmaceutical company organized around a decentralized portfolio model to discover, develop, and commercialize medicines for patients with genetic diseases. The company has FDA-approved products including acoramidis (Attruby in the US, Beyonttra internationally) for transthyretin amyloid cardiomyopathy, and multiple late-stage programs in development targeting rare genetic conditions such as achondroplasia, limb-girdle muscular dystrophy, and autosomal dominant hypocalcemia.
Themes: ["Rare genetic diseases","Transthyretin amyloidosis","Bone and skeletal disorders","Muscle disorders","Genetic disease drug development","Decentralized/hub-and-spoke biotech model"]
Fundamentals
- Price$85.89 as of 2026-07-10 close
- Market cap$16.8B as of 2026-07-12
- 1-year return+85.6% as of 2026-07-10 close
- Net margin-124.4% as of 2026-07-12
- Gross margin+95.1% as of 2026-07-12
- ROE-206.7% as of 2026-07-12
- Debt / equity8.27 as of 2026-07-12
- Revenue growth (YoY)+355.2% as of 2026-07-12
- Revenue CAGR (3y)+86.3% SEC XBRL
- Beta0.98 as of 2026-07-12
Key risks (from latest filing)
["Continued operating losses and dependence on future commercialization success of Attruby and pipeline candidates to achieve profitability; company expects losses to continue for several years","Regulatory approval risk for late-stage programs including infigratinib, BBP-418, and encaleret; failure to obtain approvals would impact future commercial potential","Competition from other therapies and commercial execution risk in launching multiple new products globally; reliance on strategic partners (Bayer in Europe, Alexion in Japan) for international distribution"]
Competitors & peers
- Ionis Pharmaceuticals
- Regeneron Pharmaceuticals
- Reata Pharmaceuticals
- Scholar Rock
- Arcturus Therapeutics
- Ultragenyx Pharmaceutical
Fundamentals: Finnhub, as of 2026-07-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.